Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Filtrar os resultados da pesquisa
Selecionar modelos de dados

Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

54 Resultados da pesquisa.

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - End of Treatment/End of Study

- 28/08/2018 - 1 Formulário, 2 Grupos de itens, 5 Elementos de dados, 1 Idioma

Grupos de itens: Therapeutic Procedure; End, Clinical Research; End

Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Blood Transfusion Record

- 28/08/2018 - 1 Formulário, 2 Grupos de itens, 8 Elementos de dados, 1 Idioma

Grupos de itens: Pre-operative Blood Donation, Blood Transfusion Record

Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Medication Record

- 28/08/2018 - 1 Formulário, 1 Grupo de itens, 8 Elementos de dados, 1 Idioma

Grupo de itens: Medication Summary

Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Autopsy Form

- 28/08/2018 - 1 Formulário, 1 Grupo de itens, 7 Elementos de dados, 1 Idioma

Grupo de itens: Autopsy

Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Unscheduled Laboratory Tests

- 28/08/2018 - 1 Formulário, 1 Grupo de itens, 6 Elementos de dados, 1 Idioma

Grupo de itens: Laboratory Procedures, Unscheduled

Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

RIETE score

- 25/01/2018 - 1 Formulário, 1 Grupo de itens, 7 Elementos de dados, 1 Idioma

Grupo de itens: RIETE score

RIETE is an ongoing registry of consecutive patients with acute venous thromboembolism (VTE). This risk score is based on six variables documented at entry and can identify VTE patients at low, intermediate, or high risk for major bleeding during the dirst three months of anticoagulant therapy. Reference: Ruíz-Giménez, N., Suárez, C., González, R., Nieto, J. A., Todolí, J. A., Samperiz, Á. L., & Monreal, M. (2008). Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. THROMBOSIS AND HAEMOSTASIS-STUTTGART-, 100(1), 26. Publication granted by RIETE Registry Coordinating Center, S & H Medical Science Service.

Input Data Elements CDSS VTE prophylaxis Nazarenko 2015

- 13/10/2016 - 1 Formulário, 1 Grupo de itens, 3 Elementos de dados, 1 Idioma

Grupo de itens: VTE prophylaxis criteria

Input Data Elements CDSS for VTE prophylaxis to evaluate the effectiveness of implementation of international and national CPGs for venous thromboembolism (VTE) prevention in form of a CDSS Published by Nazarenko et al. 2015

Input Data Elements CDSS VTE prophylaxis Woller 2015

- 13/10/2016 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma

Grupo de itens: VTE prophylaxis criteria

Input Data Elements CDSS for VTE prophylaxis:Does computerized clinical decision support improve warfarin management and decrease recurrent venous thromboembolism Published by Woller et al. 2015

Input Data Elements CDSS VTE prophylaxis: Optimize Warfarin/Anticoagulation Therapy Lin 2014 - Input Data Elements CDSS VTE prophylaxis: Optimize Warfarin/Anticoagulation Therapy Lin 2014

- 13/10/2016 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma

Grupo de itens: Risk assessment criteria

Input Data Elements CDSS for VTE prophylaxis: Optimize Warfarin/Anticoagulation Therapy to evaluate clinical outcomes of patients on warfarin therapy following CDSS in form of a personal handy-phone system-based alert system. Published by Lin et al. 2014

Input Data Elements CDSS VTE prophylaxis Beeler 2014

- 13/10/2016 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma

Grupo de itens: Risk assessment criteria

Input Data Elements CDSS for VTE prophylaxis to evaluate the effect of electronic reminders on thromboprophylaxis rates after admissions and transfers, published by Beeler et al. 2014

Input Data Elements CDSS VTE prophylaxis Zeidan 2013

- 12/10/2016 - 1 Formulário, 2 Grupos de itens, 13 Elementos de dados, 1 Idioma

Grupos de itens: Risk factors, Contraindications

Input Data Elements CDSS for VTE prophylaxis to examine the impact of „smart order set“ on VTE prophylaxis and events in medical inpatients.Published by Zeidan et al. 2013

Input Data Elements CDSS VTE prophylaxis Mitchell 2012

- 11/10/2016 - 1 Formulário, 9 Grupos de itens, 50 Elementos de dados, 1 Idioma

Grupos de itens: Patient status, Cardiovascular diseases, Gastrointestinal diseases, Pulmonary diseases, Renal diseases, Hematologic/Oncologic diseases, Gynecology, Drugs, Contraindications

Input Data Elements CDSS for VTE prophylaxis to determine wether a simple electronic reminder increases prophylaxis rates and reduces VTE rates. Published by Mitchell et al. 2012

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.